Showing 2621-2630 of 4063 results for "".
- Glaukos Featured in Numerous Scientific Abstracts at 2021 ESCRShttps://modernod.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-2021-escrs/2480335/Glaukos announced that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting, being held October 8-11, 2021, in Amsterdam, Netherlands. Key Glaucoma Presentations: P
- Report: NHS Patients Waiting More Than 9 Months on Average for Cataract Surgery in 2021https://modernod.com/news/reports-nhs-patients-waiting-more-than-9-months-on-average-for-cataract-surgery-in-2021/2480329/Reports from 12 NHS hospitals across London and Bedfordshire have revealed sharp increases in waiting times for cataract surgery from 2019 to 2021. The impact of the COVID-19 pandemic can be seen, as wai
- Alcon Presents Complete Scientific Program at ESCRS 2021https://modernod.com/news/alcon-presents-complete-scientific-program-at-escrs-2021/2480326/Alcon will present extensive data during the 2021 Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Amsterdam, Netherlands, from October 8-11. Three symposia and more than 40 abstracts featuring Alcon ophthalmic products
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- Nicox Does Not Meet Primary or Secondary Endpoints in Phase 2b Mississippi Blepharitis Trialhttps://modernod.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/Nicox SA announced the results from its Mississippi phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations o
- Aerie Announces Positive Phase 2b Study Results for Dry Eye Product Candidatehttps://modernod.com/news/aerie-announces-positive-phase-2b-study-results-for-dry-eye-product-candidate/2480279/Aerie Pharmaceuticals reported positive topline results of its phase 2b clinical study, COMET-1, for AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The randomized, double-masked, vehicle-controlled phase 2b clinical study
- Gemini Therapeutics Announces Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021https://modernod.com/news/gemini-therapeutics-announces-data-from-its-ongoing-phase-2a-study-of-gem103-at-euretina-2021/2479579/Gemini Therapeutics announced that Raj Maturi, MD, Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing phase 2a study at EURETINA 2021
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- Schwind Installs 2,000th Eye Laserhttps://modernod.com/news/schwind-installs-2000th-eye-laser/2479487/Schwind announces a milestone with the 2,000th Schwind laser system for refractive corneal surgery being installed in the Ayrshire Eye Clinic in Ayr, Scotland, by Prof. Sathish Srinivasan, founder and Medical Director